Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations. Jeon SY, Byun MS, Choi HJ, Kim YH, et al. Alzheimers Dement 2025;21:e70875.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jeon SY, Byun MS, Choi HJ, Kim YH, et al. Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations. Alzheimers Dement 2025;21:e70875.
PMID: 41225766